|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Improvements in Quality of Life and Disease-related Symptoms in Phase I Trials of the Selective Oral Epidermal Growth Factor Receptor Tyrosin Kinase Inhibitor ZD1839 in Non-Small Cell Lung Cancer and Other Solid Tumors显示文摘 | LoRusso PM Herbst RS Rischin D | 2003 | Clin Cancer Res2003，9，6： | 1 |
| 2 | Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinasc inhibitor ZD1839 in non-small cell lung cancer and other solid tumors显示文摘 | LORUSSO PM HERBST RS RISCHIN D | 2003 | Clin Cancer Res2003，9，6： | 1 |
| 3 | Demiatologic side effects associated with gefitinib therapy:clmical experience and management显示文摘 | Herbst RS Lorusso PM Purdom M | 2003 | Clin Lung Cancer2003，4，6： | 1 |
| 4 | Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab--DM 1, a HER2-targeted anti- body-drug conjugate, in patients with HER2--positive metastatic breast cancer显示文摘 | Gupta M LoRusso PM Wang B | 2012 | J Clin Pharmacol2012，52，5： | 1 |
| 5 | Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126 显示文摘 | Evelhoeh JL LoRusso PM He Z | 2004 | Clin Cancer Res2004，10，： | 1 |
| 6 | Translating clinical trials into meaningful outcomes 显示文摘 | LoRusso PM Schnipper LE Stewart DJ | 2010 | Clin Cancer Res2010，16，24： | 1 |
| 7 | Oxaliplatin in tumor other than colorectal cancer 显示文摘 | | 2000 | Oncolcgy (huntingt)2000，14，1211： | 1 |
| 8 | Improvements in quality of life and disease-ralated symptoms in phase Ⅰ trials of the selective oral epidermal growth factor receptor tyrosinc kinase inhibitor ZD1839 in non-small-cell lung cancer and other solid tumors显示文摘 | Lorusso PM Heebst RS Rischin D | 2003 | Clin Cancer Rest2003，9，6： | 1 |
| 9 | Phase 1 trial of hedge- hog pathway inhibitor vismodegib ( GDC-0449 ) in patients with re- fractory, locally advanced or metastatic solid tumors 显示文摘 | LoRusso PM Rudin CM Reddy JC | 2011 | Clin Cancer Res2011，17，8： | 1 |
| 10 | A first-in-human,first-inclass,phase (ph) Ⅰ study of systemic Hedgehog (Hh) pathway antagonist,GDC-0449,in patients (pts) with advanced solid tumors显示文摘 | Lorusso PM Rudin CM Borad MJ | 2008 | J Clin Oncol2008，26，15： | 1 |
| 11 | Inprovements in quality of life and disease-related symptoms in phase Ⅰ trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839in non-small cell lung cancer and other solid tumors显示文摘 | Herbst RS Rischin D | 2003 | Clin Cancer Res2003，9，6： | 1 |
| 12 | The investigational new drug XK469 induces GriM cell cycle arrest by p53-dependent and -independent pathways 显示文摘 | Ding ZH Parchment RE LoRusso PM | 2001 | Clin Cancer Res2001，7，： | 1 |
| 13 | Phase I phar- macokinetic and pharmacodynamic study of the oral MAPKIERK kinase inhibitor PD -0325901 in patients with advanced cancers 显示文摘 | LoRusso PM Krishnamurthi SS Rinehart JJ | 2010 | ClinCancerRes2010，16，6： | 1 |
| 14 | Phase I trial ofhedgehog pathway inhibitor vismodegib (GDC-0449) in pa- tients with refractory, locally advanced or metastatic solid tumors 显示文摘 | LoRusso PM Rudin CM Reddy JC | 2011 | Clin C~ower Res2011，17，8： | 1 |
| 15 | Inhibition of the hedgehog pathway in advanced basal-cell carcinoma显示文摘 | Von Hoff DD LoRusso PM Rudin CM | | 0，，： | 1 |
| 16 | Pharmacokinetic dose- scheduling study of hedgehog pathway inhibitor vismodegib(GDC-0449) in patients with locally advanced or metastatic solid tumors显示文摘 | Lorusso PM Jimeno A Dy G | 2011 | Clin Cancer Res2011，17，17： | 1 |
| 17 | The investigational new drug XK469 induces G(2)-M cell cycle arrest by p53-dependent and -independent pathways显示文摘 | Ding Z Parchment RE LoRusso PM | 2001 | Clin Cancer Res2001，7，11： | 1 |
| 18 | Targeting the epidermal growth factor receptor显示文摘 | El-Rayes BF LoRusso PM | 2004 | Br J Cancer2004，91，3： | 1 |
| 19 | Inhibition of the hedgehog pathway in advanced basal-cell carcinoma 显示文摘 | Von Hoff DD LoRusso PM Rudin CM | 2009 | N Engl J Med2009，361，12： | 1 |
| 20 | Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-smallcell lung, breast, colon, and pancreatic cancer显示文摘 | Rinehart J Adjei AA Lorusso PM | 2004 | J Clin Oncol2004，22，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员